Cabaletta Bio Inc (CABA)
10.17
+0.24
(+2.42%)
USD |
NASDAQ |
May 31, 16:00
10.17
0.00 (0.00%)
After-Hours: 20:00
Cabaletta Bio Cash from Financing (Quarterly): 6.855M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.855M |
| December 31, 2023 | 93.05M |
| September 30, 2023 | 0.098M |
| June 30, 2023 | 94.26M |
| March 31, 2023 | 0.226M |
| December 31, 2022 | 32.89M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.04M |
| March 31, 2022 | 0.051M |
| December 31, 2021 | 13.63M |
| September 30, 2021 | 25.34M |
| Date | Value |
|---|---|
| June 30, 2021 | 7.771M |
| March 31, 2021 | 2.165M |
| December 31, 2020 | 0.032M |
| September 30, 2020 | 0.135M |
| June 30, 2020 | -0.147M |
| March 31, 2020 | -0.044M |
| December 31, 2019 | 73.32M |
| September 30, 2019 | -2.101M |
| June 30, 2019 | -0.956M |
| March 31, 2019 | 49.66M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.101M
Minimum
Sep 2019
94.26M
Maximum
Jun 2023
17.33M
Average
0.1805M
Median
Cash from Financing (Quarterly) Benchmarks
| Editas Medicine Inc | 0.192M |
| ACADIA Pharmaceuticals Inc | 1.043M |
| Alnylam Pharmaceuticals Inc | 28.91M |
| Regeneron Pharmaceuticals Inc | 47.10M |
| Vertex Pharmaceuticals Inc | -357.50M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -23.99M |
| Cash from Investing (Quarterly) | -0.812M |
| Free Cash Flow | -66.05M |
| Free Cash Flow Per Share (Quarterly) | -0.503 |
| Free Cash Flow Yield | -14.33% |